CompanySLSNasdaqNew York, NY

Sellas Life Sciences Group

SELLAS develops cancer immunotherapies including GPS, a WT1-targeting therapeutic for hematologic malignancies and solid tumors, and SLS009, a CDK9 inhibitor in development for acute myeloid leukemia.

Stories only

SEC EDGAR ClinicalTrials.gov sellaslifesciences.com

DEF 14ASep 28Latest SEC filing

Aug 11Latest story

August 2026

Sellas reports Q2 2026 results, nears key REGAL trial milestone

Aug 11Quarterly updateSellas Life Sciences Group SLS009

July 2026

SELLAS loses arbitration against 3D Medicines over GPS milestone dispute

Jul 27Quarterly updateSellas Life Sciences Group